Autoimmune cardiomyopathies

The term autoimmune cardiomyopathies encompasses conditions in which an inappropriate immune response causally contributes to damage of the cardiac muscle.
It does not designate a single phenotype recognized by contemporary classifications: the patient may present with myocarditis, dilated cardiomyopathy, a nondilated hypokinetic phenotype, transient thickening due to edema, restrictive fibrosis or a predominantly arrhythmic substrate.
The clinically useful definition should therefore specify the cause, histologic type, inflammatory activity and structural consequence.

Autoimmunity may be limited to the heart, as in some virus-negative lymphocytic myocarditides and giant cell myocarditis, or may represent a manifestation of lupus, systemic sclerosis, inflammatory myopathy, rheumatoid arthritis, Sjogren syndrome or vasculitis.
Cardiac sarcoidosis is a granulomatous immune-mediated disease rather than a classic autoantibody-mediated disease, whereas immune checkpoint inhibitor myocarditis is an iatrogenic loss of peripheral tolerance.
Grouping these entities together facilitates pathogenetic reasoning, but does not justify uniform therapy.

Cardiac involvement in systemic diseases does not always correspond to autoimmune cardiomyopathy.
Accelerated coronary artery disease, thrombosis due to antiphospholipid syndrome, pulmonary hypertension, pericarditis, Libman-Sacks valvular disease, anemia, kidney failure and drug toxicity can cause symptoms and dysfunction without primary myocardial inflammation.
Attributing every abnormality to the autoimmune disease delays potentially treatable alternative diagnoses.

Nor does positivity for an autoantibody by itself prove the cardiac cause.
ANA and other antibodies may occur in healthy individuals, increase with age or indicate a connective tissue disease without myocarditis; anti-heart and anti-beta-1 adrenergic receptor autoantibodies are of biological interest, but are not universally validated tests for deciding on immunosuppression or immunoadsorption.
Diagnosis arises from integration of clinical probability, systemic activity, biomarkers, imaging and, when it changes management, endomyocardial biopsy.

In organ-specific forms, tolerance to cardiac antigens is lost and autoreactive lymphocyte clones recognize proteins of cardiomyocytes, the sarcolemma or the matrix.
A previous infection may initiate injury and antigen presentation through molecular mimicry, bystander activation or release of hidden epitopes, but persistence of inflammation does not prove that the virus is still present.
The transition from an infectious trigger to immune-mediated disease is a continuum, not a simple dichotomy.

CD4 and CD8 T lymphocytes, macrophages and dendritic cells produce cytokines, perforins and granzymes that directly damage cardiomyocytes.
Lymph nodes and cardiac tissue sustain B-cell activation, autoantibody production and complement amplification; profibrotic signals such as TGF-beta transform repair into scar.
The balance between effector and regulatory cells determines resolution, recurrence or chronicity.

Virus-negative lymphocytic myocarditis is defined by histologic and immunohistochemical demonstration of inflammation, with molecular analysis of the specimen not indicating a relevant cardiotropic agent.
The term virus-negative is not automatically synonymous with autoimmune: sampling, timing of biopsy, assay sensitivity and the significance of low amounts of genome must be interpreted by experienced laboratories.
Causality requires exclusion of alternatives and clinicopathologic consistency.

Giant cell myocarditis is a rare, aggressive and predominantly T-cell-mediated form characterized by multinucleated giant cells, myocyte necrosis and an inflammatory infiltrate without well-formed granulomas.
More often than other forms of myocarditis, it is associated with autoimmune diseases, thymoma and immune toxicity, and it can rapidly cause shock, ventricular tachycardia or atrioventricular block.
It is distinct from sarcoidosis, although small biopsies and borderline forms can make separation difficult.

In sarcoidosis, noncaseating granulomas involve the myocardium focally and preferentially affect the basal septum, ventricular walls and conduction system.
Active inflammation and scar coexist, generating blocks, aneurysms, dysfunction and ventricular reentry; the absence of granulomas on cardiac biopsy does not exclude a patchy disease.
Granulomatous infections must be excluded before calling the process autoimmune.

In systemic lupus erythematosus, immune complexes, complement, autoantibodies, vasculitis and endothelial dysfunction can involve the myocardium and microcirculation.
Clinically evident lupus myocarditis is less common than subclinical abnormalities, but can cause edema, necrosis, biventricular dysfunction and shock.
Premature coronary artery disease, antiphospholipid thrombosis, Libman-Sacks endocarditis and pericarditis are competing mechanisms that should be recognized separately.

In systemic sclerosis, the heart is affected by microcirculatory vasculopathy, ischemia-reperfusion episodes, inflammation and progressive matrix deposition.
The typical result is patchy fibrosis with diastolic dysfunction, reduced strain, arrhythmias and sometimes systolic failure; active myocarditis may overlap with scar.
Pulmonary arterial hypertension and interstitial lung disease additionally increase right ventricular load without constituting primary myocarditis.

Polymyositis, dermatomyositis, antisynthetase syndromes and immune-mediated necrotizing myopathy can involve cardiomyocytes and the conduction system along with skeletal muscle.
Troponin T can rise because of expression in regenerating skeletal muscle, whereas troponin I is generally more specific for the heart; no biomarker should nevertheless be interpreted in isolation from context.
Dysphagia, proximal weakness and interstitial lung disease point toward the systemic phenotype.

Rheumatoid arthritis and Sjogren syndrome are associated with systemic inflammation, endothelial dysfunction and increased cardiovascular risk, but true myocarditis is much less common than coronary artery disease, multifactorial heart failure or pericardial involvement.
Vasculitides can damage the myocardium through direct inflammation, small-vessel ischemia or coronary arteritis; in eosinophilic granulomatosis with polyangiitis, eosinophilic toxicity is an additional mechanism.
Defining the mechanism determines the choice among revascularization, anticoagulation, anti-inflammatory therapy and immunosuppression.

CTLA-4, PD-1 and PD-L1 inhibitors remove immune brakes needed for antitumor activity but also for cardiac tolerance.
Checkpoint inhibitor myocarditis often occurs early, can be associated with myositis and myasthenia, and carries substantial mortality even with preserved ejection fraction.
The T-cell infiltrate can simultaneously affect myocardium, respiratory muscles and the conduction system.

Antimalarial drugs such as hydroxychloroquine deserve an essential distinction: cumulative exposure can cause toxic cardiomyopathy from lysosomal storage, not myocardial autoimmunity.
Wall thickening, restrictive physiology, conduction blocks and vacuolization with curvilinear bodies on electron microscopy support the diagnosis.
Likewise, anthracyclines, radiation therapy, hypertension and ischemia do not become autoimmune simply because they are present in a rheumatologic patient.

Genetic susceptibility modifies the inflammatory threshold.
Pathogenic variants, particularly desmosomal but also in other structural genes, have been observed in patients with recurrent myocarditis or an arrhythmogenic phenotype, suggesting that inflammation and inherited cardiomyopathy may potentiate each other.
Persistent scar, family history or recurrence mandates not stopping at an exclusively autoimmune explanation.

Presentation depends more on the speed, site and extent of inflammation than on the name of the systemic disease.
Chest pain with ST-segment elevation and elevated troponin can mimic myocardial infarction; dyspnea and congestion may dominate in the heart failure form; palpitations, syncope or sudden death reflect the arrhythmic phenotype.
Initially normal ventricular function does not exclude severe electrical risk.

In an infarct-like syndrome, pain is often acute and may be associated with pericarditis, but coronary ischemia should be excluded according to age, risk and presentation.
In lupus and vasculitides, thrombosis, dissection, vasospasm and coronary arteritis can coexist with myocarditis.
Attributing troponin elevation to inflammation without evaluating the coronary arteries can be dangerous.

Acute heart failure ranges from fatigue and orthopnea to pulmonary edema and cardiogenic shock.
Disproportionate tachycardia, narrow pulse pressure, cold extremities, oliguria, elevated lactate and altered mental status indicate hypoperfusion and require transfer to a center capable of biopsy and mechanical support.
Fulminant myocarditis can deteriorate within hours.

Arrhythmias include ectopy, supraventricular tachycardias, atrial fibrillation, monomorphic or polymorphic ventricular tachycardia and ventricular fibrillation.
Active inflammation alters automaticity and conduction; healed scar maintains reentry circuits even when troponin and systemic inflammatory markers are normal.
Syncope in a patient with sarcoidosis, giant cell myocarditis or systemic sclerosis is a warning sign.

Second- or third-degree atrioventricular block, bundle-branch blocks and sinus node disease may be the first manifestation.
New advanced block in a nonelderly adult should prompt consideration of sarcoidosis and giant cell myocarditis, especially when accompanied by dysfunction, arrhythmias or extracardiac findings.
Recovery of conduction with therapy does not necessarily eliminate future risk.

Giant cell myocarditis tends to present with rapidly progressive heart failure, refractory ventricular arrhythmias or conduction block.
The course may initially resemble ordinary myocarditis, but lack of response, electrical instability and hemodynamic deterioration should accelerate biopsy.
Diagnostic delay reduces the opportunity to initiate combined immunosuppression before irreversible injury.

Cardiac sarcoidosis may be isolated or accompanied by hilar lymphadenopathy, pulmonary lesions, uveitis, erythema nodosum, neuropathy or hypercalcemia.
Atrioventricular block, ventricular tachycardia and noncoronary regional dysfunction are classic presentations, but none is specific.
Extracardiac disease provides a biopsy site that is often safer and more sensitive than the heart.

In lupus, myocarditis may occur during a flare with fever, arthritis, rash, cytopenias, nephritis, reduced complement and increased anti-DNA antibodies, but cardiac and systemic activity are not always parallel.
Pericardial effusion, valvular regurgitation or thrombotic events can complicate interpretation of the picture.
Lupus myocarditis may be subclinical or fulminant.

In systemic sclerosis, exertional dyspnea, reduced cardiac reserve, palpitations and signs of diastolic or right-sided dysfunction predominate.
Raynaud phenomenon, skin thickening, digital ulcers, reflux and lung disease point toward the diagnosis, but dyspnea requires separation among primary heart disease, interstitial lung disease, pulmonary hypertension, anemia and deconditioning.
Silent fibrosis may precede symptoms.

In inflammatory myopathies, proximal weakness, myalgias, dysphagia, heliotrope rash or Gottron papules may accompany palpitations and heart failure.
During cancer immunotherapy, ptosis, diplopia, dysphagia, neck weakness or breathing difficulty suggest a high-risk myocarditis-myositis-myasthenia overlap.
Respiratory assessment is urgent even when cardiac symptoms seem mild.

Chronic forms present as dilated or nondilated hypokinetic cardiomyopathy with progressive dyspnea, fatigue and reduced exercise tolerance.
Inflammation may still be active, intermittent, or exhausted, leaving only fibrosis and remodeling.
This distinction is essential because a scar does not respond to escalation of immunosuppression as an active infiltrate does.

Many patients have subclinical involvement detected by troponin, strain or magnetic resonance performed during evaluation of the systemic disease.
Prognostic significance depends on extent, activity, rhythm and the causal disease; not every mapping abnormality is equivalent to myocarditis requiring treatment.
The aim of screening is to find actionable disease without generating overdiagnosis.

Diagnosis begins by reconstructing the chronology of cardiac symptoms, systemic flares, infections, vaccinations, medications and cancer treatments.
Lupus, systemic sclerosis, myositis, vasculitis, sarcoidosis, autoimmune endocrinopathies and a family history of cardiomyopathy, arrhythmias or sudden death should be sought.
The question is not simply whether autoimmunity exists, but whether it explains the present phenotype.

Physical examination and vital signs assess congestion, hypoperfusion, friction rubs, murmurs, signs of pulmonary hypertension and extracardiac manifestations.
Rash, sclerodactyly, arthritis, proximal weakness, lymphadenopathy, neuropathy, eosinophilic asthma and ocular or pulmonary abnormalities narrow the differential diagnosis.
Apparent stability does not exclude intermittent arrhythmias.

Troponin and BNP or NT-proBNP quantify injury and stress but do not identify the cause.
Complete blood count, creatinine, electrolytes, liver function, CRP, ESR, urinalysis, ferritin and thyroid profile help assess competing organ involvement and treatment safety; eosinophils and creatine kinase point toward specific phenotypes.
A normal troponin does not exclude chronic or focal myocarditis.

Immunologic tests should be guided by pretest probability.
ANA with titer and pattern, ENA, anti-double-stranded DNA, C3 and C4, ANCA, antiphospholipid antibodies, rheumatoid factor, anti-CCP and myositis panels are valuable when they answer a clinical question; indiscriminate panels generate false positives.
Anti-heart autoantibodies do not replace biopsy and imaging and do not select therapy by themselves.

The electrocardiogram may show ST-T abnormalities, low voltage, pseudonecrosis Q waves, PR or QRS prolongation, blocks and arrhythmias.
Telemetry in the acute phase and prolonged Holter monitoring detect silent events and quantify ventricular arrhythmic burden.
A normal ECG only slightly reduces probability when symptoms and troponin findings are compelling.

Echocardiography is the first imaging test because it rapidly assesses biventricular function, wall thickness, wall motion, filling pressures, valves, pericardium and thrombi.
Global longitudinal strain can reveal dysfunction before ejection fraction declines; transient wall thickening may reflect edema rather than hypertrophy.
Regional findings do not necessarily follow a coronary territory.

Cardiac magnetic resonance characterizes edema, hyperemia, necrosis and fibrosis using T2 imaging, T1 and T2 mapping, extracellular volume and late gadolinium enhancement.
The updated Lake Louise criteria increase accuracy when at least one T2-based marker of edema and one T1-based marker of nonischemic injury are concordant.
A negative magnetic resonance scan does not exclude very early, focal, treated or histologically specific disease.

The distribution of late enhancement suggests but does not establish the etiology.
Sarcoidosis may produce multifocal subepicardial, mid-wall or transmural lesions, often septal; systemic sclerosis may show diffuse or patchy fibrosis; lymphocytic myocarditis often preferentially involves the inferolateral wall.
Overlap mandates clinical integration.

FDG-PET detects inflammatory metabolism and is particularly useful in cardiac sarcoidosis, for extracardiac distribution and therapeutic response.
Physiologic myocardial glucose suppression by dietary preparation and fasting is essential; diffuse uptake from inadequate preparation does not demonstrate myocarditis.
PET and magnetic resonance provide complementary information on activity and scar.

Coronary CT angiography or coronary angiography is indicated when age, risk, pain, ECG or the distribution of injury do not permit exclusion of a coronary syndrome.
In lupus and antiphospholipid syndrome, thrombosis, embolism and accelerated atherosclerosis should be considered; in vasculitides, inflammatory stenoses and aneurysms.
Microvascular dysfunction may require dedicated assessment.

Endomyocardial biopsy is recommended or strongly considered when the result can rapidly change therapy: shock or fulminant heart failure, refractory ventricular arrhythmias, advanced block, lack of improvement, suspected giant cell or eosinophilic myocarditis, sarcoidosis or checkpoint inhibitor myocarditis.
The specimen requires histology, immunohistochemistry and molecular testing for pathogens, with direct communication between clinician and pathologist.
Multiple samples and imaging- or mapping-guided biopsy can reduce sampling error.

The Dallas criteria identify infiltrates with nonischemic necrosis, but conventional staining alone has low sensitivity in focal forms.
Immunohistochemistry quantifies T cells, macrophages and activation molecules; electron microscopy can demonstrate hydroxychloroquine toxicity.
The presence of viral genome should be quantified and interpreted: detection of a sequence is not always equivalent to active causality.

The differential diagnosis includes myocardial infarction, Takotsubo syndrome, sepsis, genetic cardiomyopathy, amyloidosis, Fabry disease, iron overload, tachycardiomyopathy, endocrinopathies, cancer therapy-related toxicity and hydroxychloroquine cardiomyopathy.
In systemic diseases, the pericardium, valves, coronary arteries, lungs and right ventricle should be evaluated separately.
An autoimmune diagnosis is only as strong as the reasoned exclusion of its mimics.

Genetic testing is indicated when there is family history, recurrence, an arrhythmogenic phenotype, persistent scar or dysfunction disproportionate to immune activity.
Finding a pathogenic variant does not negate the inflammatory episode, and finding autoimmunity does not negate familial risk.
The result should be interpreted with genetic counseling and, when appropriate, cascade screening.

Follow-up repeats symptoms, examination, ECG, biomarkers, echocardiography and rhythm monitoring at a frequency proportionate to risk.
Magnetic resonance or PET assesses resolution of edema, residual activity and scar, but timing depends on the entity, treatment and clinical decision.
Systemic remission does not automatically guarantee cardiac remission.

Treatment has four simultaneous goals: stabilize hemodynamics and rhythm, control inflammation when reversible, treat the causal disease and prevent treatment-related harm.
Shock, sustained arrhythmias or advanced block require intensive care and a center with biopsy, electrophysiology, mechanical support and transplantation capabilities.
Immunosuppression does not replace cardiovascular support.

In heart failure with reduced function, when blood pressure, kidney function and the clinical phase allow, guideline-recommended heart failure therapies are used: renin-angiotensin system modulation or an ARNI, a beta-blocker, a mineralocorticoid receptor antagonist and an SGLT2 inhibitor.
Diuretics treat congestion, whereas inotropes and vasopressors are reserved for hypoperfusion.
During the unstable phase, medications are introduced and titrated cautiously.

Temporary circulatory support can provide a bridge to recovery, diagnosis, a durable device or transplantation.
The choice among an intra-aortic balloon pump, a microaxial flow pump, venoarterial ECMO and other configurations depends on the ventricle involved, oxygenation and the expertise of the center.
Biopsy should not be delayed when histologic definition changes urgent treatment.

Immunosuppression is appropriate in defined autoimmune forms, giant cell myocarditis, symptomatic active sarcoidosis, some eosinophilic myocarditides, checkpoint inhibitor myocarditis and systemic disease involvement.
It is not indicated empirically for every dilated cardiomyopathy or an isolated positive ANA.
Active and latent infections should be sought with urgency proportionate to severity, without delaying lifesaving therapies in settings where immune-mediated injury is highly likely.

In chronic virus-negative inflammatory cardiomyopathy, the TIMIC study evaluated prednisone and azathioprine for six months in symptomatic patients with dysfunction, biopsy-documented inflammation and negative molecular viral testing.
The observed improvement and twenty-year follow-up support personalized therapy in that population, not automatic extension to patients without biopsy confirmation.
Activity, infection, toxicity and response should be reassessed.

Giant cell myocarditis requires early combined immunosuppression, generally a corticosteroid together with a calcineurin inhibitor and an additional antimetabolite according to the center's protocol.
Steroid monotherapy is often insufficient; infections, nephrotoxicity, cytopenias and interactions require close monitoring.
Mechanical support and transplant evaluation proceed in parallel when response is inadequate.

In cardiac sarcoidosis with clinical manifestations and inflammatory activity, glucocorticoids are first-line therapy, and methotrexate, azathioprine, mycophenolate or other drugs can reduce steroid exposure.
Dose and duration are adapted to conduction, arrhythmias, function and PET findings, recognizing that scar may remain arrhythmogenic even after uptake is suppressed.
Biologic therapies are reserved for refractory disease and expert centers.

Severe lupus myocarditis is generally treated with high-dose glucocorticoids, often intravenous methylprednisolone, with cyclophosphamide, mycophenolate, azathioprine, rituximab or immunoglobulins added according to severity, organs involved and response.
Specific evidence derives mainly from series and case reports rather than large randomized cardiac trials.
Infection, coronary artery disease, antiphospholipid thrombosis and hydroxychloroquine toxicity should be addressed separately.

In systemic sclerosis, documented active myocarditis may require mycophenolate or other immunosuppressants selected with rheumatology, whereas established fibrosis primarily requires cardiologic therapy and management of complications.
Glucocorticoids, especially at high doses, increase the risk of scleroderma renal crisis and should not be prescribed lightly.
Blood pressure and kidney function should be monitored, and interstitial lung disease and pulmonary hypertension treated through dedicated pathways.

In inflammatory myopathies, control of systemic disease may require corticosteroids, mycophenolate, azathioprine, methotrexate, immunoglobulins, rituximab or other therapies guided by subtype.
The heart, respiratory muscles and swallowing should be monitored together.
In rheumatoid arthritis and other connective tissue diseases, the drug is chosen according to the causal manifestation, taking into account that some TNF inhibitors are not appropriate in moderate or severe heart failure.

In immune checkpoint inhibitor myocarditis, cancer therapy is withheld and high-dose intravenous methylprednisolone is started promptly in probable or confirmed cases, without waiting for all results if the presentation is life-threatening.
Steroid-refractory disease requires multidisciplinary discussion of mycophenolate, abatacept, ruxolitinib or other rescue strategies; evidence for many options remains observational.
In the presence of heart failure, infliximab may be harmful and should be avoided or considered with extreme caution.

Electrical management includes correction of precipitating factors, antiarrhythmic drugs, cardioversion, temporary pacing and ablation in selected cases.
A pacemaker or defibrillator is chosen considering reversibility, scar, syncope, ventricular tachycardia and the specific disease; sarcoidosis and giant cell myocarditis may retain high risk even after recovery of ejection fraction.
A wearable defibrillator can serve as a bridge in selected scenarios, not as a universal solution.

Intense physical activity is suspended during the acute phase.
Return to sport requires resolution of symptoms, normalization or stabilization of biomarkers, functional recovery and absence of significant arrhythmias, with imaging and exercise testing according to risk.
Graded rehabilitation avoids both premature exposure and unnecessary prolonged inactivity.

Prognosis depends on histologic type and phenotype.
Shock, severe biventricular dysfunction, giant cells, ventricular arrhythmias, advanced block and extensive scar are adverse markers; early recovery, causal control and absence of arrhythmias improve the course.
Return of ejection fraction to normal does not erase scar or the risk of recurrence.

Follow-up is shared between the cardiologist and the specialist managing the underlying disease.
Immunosuppressive dose, infection prophylaxis, vaccinations, bone density, blood pressure, kidney function, blood count, liver function and fertility are integrated with rhythm and imaging.
Treatment is tapered gradually and guided by clinical, biological and imaging remission.

Cardiogenic shock is the most immediately lethal complication of fulminant myocarditis.
It may be biventricular and associated with respiratory failure, kidney, liver and neurologic injury; inflammatory vasoplegia and arrhythmias worsen hypoperfusion.
Early recognition allows support before multiorgan injury makes cardiac recovery ineffective.

Progression to dilated or nondilated hypokinetic cardiomyopathy results from myocyte loss, remodeling and persistence of inflammation.
Some patients recover completely, whereas others retain dysfunction or relapse after apparent remission.
Functional mitral or tricuspid regurgitation can amplify congestion and dilation.

Interstitial fibrosis and replacement scar form the bridge between inflammation and chronic arrhythmia.
Ventricular tachycardia and ventricular fibrillation can occur during the active phase or years later, when inflammatory markers are normal.
The amount and location of late enhancement contribute to risk stratification, without a threshold valid for all entities.

Atrioventricular block may resolve with control of inflammation or become permanent.
Sarcoidosis and giant cell myocarditis can progress despite initially effective pacing, with ventricular tachycardias and dysfunction.
The device treats the electrical consequence, not the underlying disease.

Ventricular and atrial thrombi occur in the presence of severe dysfunction, aneurysms, stasis, atrial fibrillation or antiphospholipid syndrome.
Cerebral, systemic or pulmonary embolism may be the first complication; anticoagulation follows the indication, site, bleeding risk and mechanism.
Systemic autoimmune thrombosis should not be confused with a direct effect of myocarditis.

Pericarditis, effusion and, rarely, tamponade can accompany lupus, rheumatoid arthritis, vasculitides and myocarditis.
Immune-mediated or thrombotic valvular diseases, such as Libman-Sacks endocarditis, increase embolic risk and the infectious differential.
Every cardiac structure should therefore be evaluated even when the diagnostic pathway begins with the myocardium.

In systemic sclerosis, pulmonary arterial hypertension, interstitial lung disease and myocardial fibrosis can converge in right ventricular dysfunction.
Prognosis depends on correctly attributing the relative contributions because diuretics, pulmonary vasodilators, immunosuppression and treatment of interstitial lung disease target different mechanisms.
Right heart catheterization is necessary when pulmonary hypertension must be confirmed and classified.

Autoimmune disease can damage the kidneys, lungs, nervous system and muscle simultaneously with the heart.
In checkpoint inhibitor overlap syndromes, respiratory muscle paralysis can cause death even while ventricular function improves; in lupus, nephritis and thrombosis affect volume and treatment.
Prognosis is multiorgan and cannot be summarized by ejection fraction.

Infections are a complication of the disease and, especially, of immunosuppression.
Opportunistic pneumonia, reactivation of tuberculosis or hepatitis, herpes zoster, sepsis and hypogammaglobulinemia require screening, vaccinations, prophylaxis and early diagnosis according to the regimen.
Fever during therapy should not automatically be attributed to an autoimmune flare.

Corticosteroids cause hyperglycemia, hypertension, osteoporosis, myopathy, psychiatric disturbances and infections; in systemic sclerosis they can precipitate renal crisis.
Cyclophosphamide carries risks of cytopenias, infertility, cystitis and malignancy; calcineurin inhibitors cause nephrotoxicity and hypertension; azathioprine and mycophenolate can cause hematologic, hepatic or reproductive toxicity.
Monitoring treatment is an integral part of clinical cardiology.

Recurrence may follow medication tapering, renewed systemic activation or iatrogenic re-exposure.
Troponin elevation, ECG changes or new arrhythmias may precede symptoms, while preexisting scar makes it difficult to distinguish activity from sequelae.
A written surveillance plan reduces both diagnostic delay and unjustified escalation.

Heart transplantation is possible in irreversible heart failure, but requires assessment of systemic disease activity, other organs, infections and the underlying malignancy.
Giant cell myocarditis can recur in the graft and sarcoidosis can reactivate, although transplantation remains effective therapy in selected patients.
Post-transplant immunosuppression is individualized.

Pregnancy and the puerperium modify hemodynamics and immunity, with risks depending on ventricular function, arrhythmias, pulmonary hypertension, systemic activity and teratogenic drugs.
Mycophenolate, methotrexate and cyclophosphamide require specific planning and should not be stopped or substituted without medical supervision.
Multidisciplinary preconception counseling is part of prevention.

Anxiety, fear of sudden death, physical limitation and uncertainty about recurrence can persist after recovery.
Systemic symptoms, medication effects and implantable devices influence work, sexuality and quality of life.
Rehabilitation, psychological support and clear communication of goals complete care.